Katzenschlager R, Koppensteiner R, Minar E, Muhm M, Stümpflen A, Ugurluoglu A, Huk I, Ehringer H
Universitätsklinik für Innere Medizin II, Abteilung für Angiologie, Wien.
Vasa. 1993;22(4):355-7.
The case of a 70-year-old woman suffering from a long occlusion of the right branch of an aortobifemoral dacron-graft implanted six years ago is reported. Patency could be achieved by a systemic application of an ultrahigh dose of urokinase (UHUK = 9,000,000 I.U/6 h, intermittent daily application, two cycles). As a major complication macro-embolism to the popliteal artery and to the superficial femoral artery occurred, however. A further cycle of UHUK, local thrombolytic therapy (12 mg rtPA) and surgical thrombectomy failed to achieve persistent recanalization. So the patient finally had to be provided with a femoro-crural composite bypass. In conclusion, in a systemic thrombolytic therapy of occlusions of dacron grafts in the aorto-iliacal area a standard dose of urokinase (initial dose 600,000 I.U., maintenance dose 150,000 I.U./h, infusion pump) is recommended.
报告了一名70岁女性的病例，该患者6年前植入的主动脉双股涤纶移植物右支出现长期闭塞。通过全身应用超高剂量尿激酶（UHUK = 9,000,000国际单位/6小时，间歇性每日应用，两个周期）可实现血管通畅。然而，出现了一个主要并发症，即腘动脉和股浅动脉发生大栓子栓塞。进一步的UHUK周期、局部溶栓治疗（12毫克重组组织型纤溶酶原激活剂）和手术取栓均未能实现持续再通。因此，患者最终不得不接受股-小腿复合旁路移植术。总之，在对主动脉-髂动脉区域涤纶移植物闭塞进行全身溶栓治疗时，推荐使用标准剂量的尿激酶（初始剂量600,000国际单位，维持剂量150,000国际单位/小时，输液泵）。
